Press release
Anavex Life Sciences to Present at Upcoming Global Healthcare Conferences
Cantor Fitzgerald Global Healthcare Conference 2020 and H.C. Wainwright 22nd Annual Global Investment Conference NEW YORK, Sept. 08, 2020 (GLOBE NEWSWIRE) --
About this update from Anavex Life Sciences Corp.
[{"type":"text","content":"Cantor Fitzgerald Global Healthcare Conference 2020 and H.C. Wainwright 22nd Annual Global Investment Conference\nNEW YORK, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) diseases, today announced that its President & Chief Executive Officer, Christopher U. Missling, PhD, will present a company update at both the Cantor Fitzgerald Global Healthcare Conference 2020 and the H.C. Wainwright 22nd Annual Global Investment Conference. The conferences are both virtual and details of the presentations are below.\n Cantor Global Healthcare Conference 2020When: Thursday, September 17th, 2020 at 12:40 pm ET.A live webcast is available at: https://www.webcaster4.com/Webcast/Page/2495/37416.H.C. Wainwright 22nd Annual Global Investment ConferenceWhen: Monday, September 14th, 2020 at 12:00 pm ET.A live webcast is available to clients of the firm at https://hcwevents.com/. About Anavex Life Sciences Corp. Anavex Life Sciences Corp. (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) diseases, pain and various types of cancer. Anavex’s lead drug candidate, ANAVEX®2-73 (blarcamesine), recently completed a successful Phase 2a clinical trial for Alzheimer’s disease. ANAVEX®2-73 (blarcamesine) is an orally available drug candidate that restores cellular homeostasis by targeting sigma-1 and muscarinic receptors. Preclinical studies demonstrated its potential to halt and/or reverse the course of Alzheimer’s disease. ANAVEX®2-73 (blarcamesine) also exhibited anticonvulsant, anti-amnesic, neuroprotective and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy. The Michael J. Fox Foundation for Parkinson’s Research previously awarded Anavex a research grant, which fully funded a preclinical study to develop ANAVEX®2-73 (blarcame...